153 related articles for article (PubMed ID: 38203393)
21. Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy.
Takada M; Higuchi T; Tozuka K; Takei H; Haruta M; Watanabe J; Kasai F; Inoue K; Kurosumi M; Miyazaki M; Sato-Otsubo A; Ogawa S; Kaneko Y
BMC Cancer; 2013 May; 13():241. PubMed ID: 23679233
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer.
Yardley DA; Raefsky E; Castillo R; Lahiry A; Locicero R; Thompson D; Shastry M; Burris HA; Hainsworth JD
Clin Breast Cancer; 2011 Oct; 11(5):297-305. PubMed ID: 21729666
[TBL] [Abstract][Full Text] [Related]
23. Expression, Clinical Significance, and Functional Prediction of MNX1 in Breast Cancer.
Tian T; Wang M; Zhu Y; Zhu W; Yang T; Li H; Lin S; Dai C; Deng Y; Song D; Li N; Zhai Z; Dai ZJ
Mol Ther Nucleic Acids; 2018 Dec; 13():399-406. PubMed ID: 30368216
[TBL] [Abstract][Full Text] [Related]
24. Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer.
Fernandez-Martinez A; Krop IE; Hillman DW; Polley MY; Parker JS; Huebner L; Hoadley KA; Shepherd J; Tolaney S; Henry NL; Dang C; Harris L; Berry D; Hahn O; Hudis C; Winer E; Partridge A; Perou CM; Carey LA
J Clin Oncol; 2020 Dec; 38(35):4184-4193. PubMed ID: 33095682
[TBL] [Abstract][Full Text] [Related]
25. Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Liu S; Chen B; Burugu S; Leung S; Gao D; Virk S; Kos Z; Parulekar WR; Shepherd L; Gelmon KA; Nielsen TO
JAMA Oncol; 2017 Nov; 3(11):e172085. PubMed ID: 28750133
[TBL] [Abstract][Full Text] [Related]
26. Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status.
Nuciforo PG; Aura C; Holmes E; Prudkin L; Jimenez J; Martinez P; Ameels H; de la Peña L; Ellis C; Eidtmann H; Piccart-Gebhart MJ; Scaltriti M; Baselga J
Ann Oncol; 2015 Jul; 26(7):1494-500. PubMed ID: 25851628
[TBL] [Abstract][Full Text] [Related]
27. RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer.
Sanz-Moreno A; Palomeras S; Pedersen K; Morancho B; Pascual T; Galván P; Benítez S; Gomez-Miragaya J; Ciscar M; Jimenez M; Pernas S; Petit A; Soler-Monsó MT; Viñas G; Alsaleem M; Rakha EA; Green AR; Santamaria PG; Mulder C; Lemeer S; Arribas J; Prat A; Puig T; Gonzalez-Suarez E
Breast Cancer Res; 2021 Mar; 23(1):42. PubMed ID: 33785053
[TBL] [Abstract][Full Text] [Related]
28. A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer.
Masuda N; Ohtani S; Takano T; Inoue K; Suzuki E; Nakamura R; Bando H; Ito Y; Ishida K; Yamanaka T; Kuroi K; Yasojima H; Kasai H; Takasuka T; Sakurai T; Kataoka TR; Morita S; Ohno S; Toi M
Breast Cancer Res Treat; 2020 Feb; 180(1):135-146. PubMed ID: 31953696
[TBL] [Abstract][Full Text] [Related]
29. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy.
Yang X; Rao J; Yang W; Shui R
Target Oncol; 2018 Dec; 13(6):757-767. PubMed ID: 30406444
[TBL] [Abstract][Full Text] [Related]
31. HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade.
Prat A; Pascual T; De Angelis C; Gutierrez C; Llombart-Cussac A; Wang T; Cortés J; Rexer B; Paré L; Forero A; Wolff AC; Morales S; Adamo B; Brasó-Maristany F; Vidal M; Veeraraghavan J; Krop I; Galván P; Pavlick AC; Bermejo B; Izquierdo M; Rodrik-Outmezguine V; Reis-Filho JS; Hilsenbeck SG; Oliveira M; Dieci MV; Griguolo G; Fasani R; Nuciforo P; Parker JS; Conte P; Schiff R; Guarneri V; Osborne CK; Rimawi MF
J Natl Cancer Inst; 2020 Jan; 112(1):46-54. PubMed ID: 31037288
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trial.
Masuda N; Toi M; Yamamoto N; Iwata H; Kuroi K; Bando H; Ohtani S; Takano T; Inoue K; Yanagita Y; Kasai H; Morita S; Sakurai T; Ohno S
Breast Cancer; 2018 Jul; 25(4):407-415. PubMed ID: 29445928
[TBL] [Abstract][Full Text] [Related]
33. Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.
Rimawi MF; De Angelis C; Contreras A; Pareja F; Geyer FC; Burke KA; Herrera S; Wang T; Mayer IA; Forero A; Nanda R; Goetz MP; Chang JC; Krop IE; Wolff AC; Pavlick AC; Fuqua SAW; Gutierrez C; Hilsenbeck SG; Li MM; Weigelt B; Reis-Filho JS; Kent Osborne C; Schiff R
Breast Cancer Res Treat; 2018 Feb; 167(3):731-740. PubMed ID: 29110152
[TBL] [Abstract][Full Text] [Related]
34. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.
Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L
Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069
[TBL] [Abstract][Full Text] [Related]
35. Pyrotinib-based treatments in HER2-positive breast cancer patients with brain metastases.
Ma X; Li Y; Li L; Gao C; Liu D; Li H; Zhao Z; Zhao B
Ann Med; 2022 Dec; 54(1):3085-3095. PubMed ID: 36331291
[TBL] [Abstract][Full Text] [Related]
36. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
de Azambuja E; Holmes AP; Piccart-Gebhart M; Holmes E; Di Cosimo S; Swaby RF; Untch M; Jackisch C; Lang I; Smith I; Boyle F; Xu B; Barrios CH; Perez EA; Azim HA; Kim SB; Kuemmel S; Huang CS; Vuylsteke P; Hsieh RK; Gorbunova V; Eniu A; Dreosti L; Tavartkiladze N; Gelber RD; Eidtmann H; Baselga J
Lancet Oncol; 2014 Sep; 15(10):1137-46. PubMed ID: 25130998
[TBL] [Abstract][Full Text] [Related]
37. Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment.
Cufí S; Vazquez-Martin A; Oliveras-Ferraros C; Corominas-Faja B; Urruticoechea A; Martin-Castillo B; Menendez JA
Oncotarget; 2012 Dec; 3(12):1600-14. PubMed ID: 23307622
[TBL] [Abstract][Full Text] [Related]
38. HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.
Hanker AB; Garrett JT; Estrada MV; Moore PD; Ericsson PG; Koch JP; Langley E; Singh S; Kim PS; Frampton GM; Sanford E; Owens P; Becker J; Groseclose MR; Castellino S; Joensuu H; Huober J; Brase JC; Majjaj S; Brohée S; Venet D; Brown D; Baselga J; Piccart M; Sotiriou C; Arteaga CL
Clin Cancer Res; 2017 Aug; 23(15):4323-4334. PubMed ID: 28381415
[No Abstract] [Full Text] [Related]
39. Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial.
Powles RL; Redmond D; Sotiriou C; Loi S; Fumagalli D; Nuciforo P; Harbeck N; de Azambuja E; Sarp S; Di Cosimo S; Huober J; Baselga J; Piccart-Gebhart M; Elemento O; Pusztai L; Hatzis C
JAMA Oncol; 2018 Nov; 4(11):e181564. PubMed ID: 29902299
[TBL] [Abstract][Full Text] [Related]
40. Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab.
Shinde AM; Zhai J; Yu KW; Frankel P; Yim JH; Luu T; Kruper L; Vito C; Shaw S; Vora NL; Kirschenbaum M; Somlo G
Breast; 2015 Feb; 24(1):18-23. PubMed ID: 25467313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
